^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Published date:
10/16/2023
Excerpt:
This is an open-label, multi-center, multiple cohorts, single arm study to evaluate the efficacy, safety and tolerability of KN046 in NSCLC. Subjects with EGFR sensitizing mutation (Ex19del or L858R), who had failed from prior EGFR-TKI(s) without platinum-based chemotherapy were enrolled. All subjects enrolled received KN046 5 mg/kg Q3W combined with chemotherapy (Pemetrexed, 500 mg/m2, Q3W and carboplatin AUC5, Q3W)....KN046 demonstrated encouraging OS benefit and a favorable safety profile in advanced NSCLC with EGFR sensitivity mutation who progressed after EGFR-TKI(s).
Trial ID:
Source:
Title:
1034P - A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EFGR-TKIs
Published date:
09/05/2022
Excerpt:
This is an open-label, multi-center, multiple cohorts, single arm study to evaluate the efficacy, safety and tolerability of KN046 in NSCLC. Subjects with EGFR sensitivity mutation (Ex19del or L858R), who had failed from prior EFGR-TKIs without platinum-based chemotherapy were enrolled....Among all 26 subjects, the ORR was 26.9% (7/26, 95% CI, 11.57, 47.79%), disease control rate (DCR) was 80.8% (21/26, 95% CI, 60.65, 93.45%) with 7 PR and 14 SD. Clinical benefit rate (CBR) was 65.4% (17/26, 95% CI, 44.33, 82.79%). Median progression-free survival (mPFS) was 5.52 months (95% CI, 4.17, 6.77) and median overall survival (mOS) was 12.68 months (95% CI, 11.4).
Trial ID:
